| Minnesota                                                               |   | 41-1448837                                   |
|-------------------------------------------------------------------------|--------|----------------------------------------------|
| (State      or other jurisdictionof      incorporation or organization) |   | (I.R.S.      Employer Identification Number) |

| Large      accelerated filer       o                 | Accelerated      filer                 o |
|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
|                                                                                    |                                                                                                                          |
| Non-accelerated      filer          o | Smaller      reporting company       x                                                     |

----

SPECTRASCIENCE, INC.

| PART      I   | FINANCIAL      INFORMATION:                                                                           |   |   | 3      |   |
|---------------|-------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|
|          |                                                                                                  |   |   |   |   |
| Item      1.  | Financial      Statements (Unaudited)                                                                 |   |   | 3      |   |
|          |                                                                                                  |   |   |   |   |
| Item      2.  | Management’s      Discussion and Analysis of Financial Condition and Results of      Operations |   |   | 11     |   |
|          |                                                                                                  |   |   |   |   |
| Item      3.  | Quantitative      and Qualitative Disclosures About Market Risk                                       |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      4.  | Controls      and Procedures                                                                          |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| PART      II  | OTHER      INFORMATION                                                                                |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      1.  | Legal      Proceedings                                                                                |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      1A. | Risk      Factors                                                                                     |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      2.  | Unregistered      Sales of Equity Securities and Use of Proceeds                                      |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      3.  | Defaults      Upon Senior Securities                                                                  |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      4.  | (Removed      and Reserved)                                                                           |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      5.  | Other      Information                                                                                |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      6.  | Exhibits                                                                                              |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| SIGNATURES    |                                                                                                  |   | 15     |   |

----

|                                                                                                                                                                   |   | September      30,2010 |        |   | December31,2009 |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------|-------------|--------|-----------------|--------|
| ASSETS                                                                                                                                                                 |   |                   |        |   |            |   |
| Current      assets:                                                                                                                                                   |   |                   |        |   |            |   |
| Cash      and cash equivalents                                                                                                                                         |   | $                      | 4,059,844   |   |            | $      | 3,408,237 |   |
| Accounts      receivable (net)                                                                                                                                         |   |                   | 9,500       |   |            |   | 40,271 |   |
| Inventories      (net of allowances)                                                                                                                                   |   |                   | 507,755     |   |            |   | 405,675 |   |
| Prepaid      expenses and other current assets                                                                                                                         |   |                   | 64,769      |   |            |   | 195,568 |   |
| Total      current assets                                                                                                                                              |   |                   | 4,641,868   |   |            |   | 4,049,751 |   |
| Fixed      assets, net                                                                                                                                                 |   |                   | 62,994      |   |            |   | 1,139,839 |   |
| Patents,      net                                                                                                                                                      |   |                   | 2,728,808   |   |            |   | 2,915,984 |   |
| TOTAL      ASSETS                                                                                                                                                      |   | $                      | 7,433,670   |   |            | $      | 8,105,574 |   |
|                                                                                                                                                                   |   |                   |        |   |            |   |   |   |
| LIABILITIES      AND SHAREHOLDERS’ EQUITY                                                                                                                        |   |                   |        |   |            |   |   |   |
| Current      liabilities:                                                                                                                                              |   |                   |        |   |            |   |   |   |
| Accounts      payable                                                                                                                                                  |   | $                      | 185,571     |   |            | $      | 219,783 |   |
| Accrued      liabilities                                                                                                                                               |   |                   | 77,981      |   |            |   | 167,475 |   |
| Total      current liabilities                                                                                                                                         |   |                   | 263,552     |   |            |   | 387,258 |   |
|                                                                                                                                                                   |   |                   |        |   |            |   |   |   |
| SHAREHOLDERS’      EQUITY                                                                                                                                        |   |                   |        |   |            |   |   |   |
|                                                                                                                                                                   |   |                   |        |   |            |   |   |   |
| Series      B Convertible Preferred Stock, $.01 par value:                                                                                                             |   |                   |        |   |            |   |   |   |
| Authorized      – 25,000,000 shares; shares issued and outstanding – 2,835,000 shares at      September 30, 2010 (25,000,000 shares at December 31,2009)   |   |                   | 28,350      |   |            |   | 250,000 |   |
| Series      C Convertible Preferred Stock, $0.01 par value:                                                                                                            |   |                   |        |   |            |   |   |   |
| Authorized—25,000,000      shares; shares issued and outstanding – 1,000,000 shares at September 30,      2010 (-0- shares at December 31, 2009)           |   |                   | 10,000      |   |            |   | - |   |
| Common      stock, $.01 par value:                                                                                                                                     |   |                   |        |   |            |   |   |   |
| Authorized—175,000,000      shares; shares issued and outstanding – 107,699,540 shares at September      30, 2010 (70,142,615 shares at December 31, 2009) |   |                   | 1,076,995   |   |            |   | 701,426 |   |
| Additional      paid-in capital                                                                                                                                        |   |                   | 30,298,528  |   |            |   | 25,511,360 |   |
| Accumulated      (deficit)                                                                                                                                             |   |                   | (24,243,755 | )      |            |   | (18,744,470 | ) |
| TOTAL      SHAREHOLDERS’ EQUITY                                                                                                                                  |   |                   | 7,170,118   |   |            |   | 7,718,316 |   |
| TOTAL      LIABILITIES AND SHAREHOLDERS’ EQUITY                                                                                                                  |   | $                      | 7,433,670   |   |            | $      | 8,105,574 |   |

----

|                                                                      |   | Three      Months EndedSeptember      30, |       |   | Nine      Months EndedSeptember      30, |   |
|---------------------------------------------------------------------------|--------|-------------------------------------------|------------|--------|------------------------------------------|--------|
|                                                                      |   | 2010                                      |       |   | 2009                                     |   |   | 2010 |   |   | 2009 |   |
| Revenue                                                                   |   | $                                         | 3,150      |   |                                     | $      | 1,875 |   |   | $ | 22,400 |   |   | $ | 122,266 |   |
| Cost      of revenue                                                      |   |                                      | 1,694      |   |                                     |   | 638 |   |   |   | 5,443 |   |   |   | 81,418 |   |
| Gross      profit                                                         |   |                                      | 1,456      |   |                                     |   | 1,237 |   |   |   | 16,957 |   |   |   | 40,848 |   |
|                                                                      |   |                                      |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Operating      expenses:                                                  |   |                                      |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Research      and development                                             |   |                                      | 1,085,076  |   |                                     |   | 445,888 |   |   |   | 1,773,071 |   |   |   | 1,180,051 |   |
| General      and administrative                                           |   |                                      | 516,535    |   |                                     |   | 565,130 |   |   |   | 1,509,448 |   |   |   | 1,555,441 |   |
| Sales      and marketing                                                  |   |                                      | 103,485    |   |                                     |   | 104,479 |   |   |   | 306,668 |   |   |   | 288,587 |   |
| Total      operating expenses                                             |   |                                      | 1,705,096  |   |                                     |   | 1,115,497 |   |   |   | 3,589,187 |   |   |   | 3,024,079 |   |
| Operating      (loss)                                                     |   |                                      | (1,703,640 | )      |                                     |   | (1,114,260 | ) |   |   | (3,572,230 | ) |   |   | (2,983,231 | ) |
|                                                                      |   |                                      |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Other      expense, net                                                   |   |                                      | 1,882      |   |                                     |   | 723 |   |   |   | 431 |   |   |   | 21 |   |
| Net      (loss)                                                           |   |                                      | (1,701,758 | )      |                                     |   | (1,113,537 | ) |   |   | (3,572,661 | ) |   |   | (2,983,252 | ) |
|                                                                      |   |                                      |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Deemed      dividend on preferred stock                                   |   |                                      | -          |   |                                     |   | (544,924 | ) |   |   | (1,836,319 | ) |   |   | (836,879 | ) |
| Accumulated      but unpaid dividend on preferred stock                   |   |                                      | -          |   |                                     |   |  (21,811 | ) |   |   | (15,850 | ) |   |   | (21,811 | ) |
|     Net      (loss) applicable to common shareholders |   | $                                         | (1,701,758 | )      |                                     |   | (1,680,272 | ) |   | $ | (5,424,830 | ) |   | $ | (3,841,942 | ) |
| Basic      and diluted net (loss) per share                               |   | $                                         | (0.02      | )      |                                     | $      | (0.02 | ) |   | $ | (0.06 | ) |   | $ | (0.06 | ) |
|     Weighted      average common shares outstanding   |   |                                      | 95,326,605 |   |                                     |   | 69,774,282 |   |   |   | 87,345,937 |   |   |   | 69,616,447 |   |

----

|                                              |   | Preferred      Stock |        |   | Common      Stock |   |     | AdditionalPaid-In |   |   | Accumulated |   |   | TotalShareholders’ |      |
|---------------------------------------------------|--------|----------------------|-------------|--------|-------------------|--------|----------|-------------------|--------|--------|-------------|--------|--------|--------------------------|-----------|
|                                              |   | Shares               |        |   | Amount            |   |     | Shares            |   |   | Amount      |   |   | Capital                  |      |   | Deficit |   |   | Equity |   |
| Balance,      December 31, 2009                   |   |                 | 25,000,000  |   |              | $      | 250,000  |              |   |   | 70,142,615  |   |   | $                        | 701,426   |   |   | $ | 25,511,360 |   |   | $ | (18,744,470 | ) |   | $ | 7,718,316 |   |
|                                              |   |                 |        |   |              |   |     |              |   |   |        |   |   |                     |      |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock      based compensation – consultants |   |                 |        |   |              |   |     |              |   |   |        |   |   |                     |      |   |   |   | 15,282 |   |   |   |   |   |   |   | 15,282 |   |
| Stock      based compensation – employees   |   |                 |        |   |              |   |     |              |   |   |        |   |   |                     |      |   |   |   | 196,445 |   |   |   |   |   |   |   | 196,445 |   |
| Common      stock issued for services             |   |                 |        |   |              |   |     |              |   |   | 400,000     |   |   |                     | 4,000     |   |   |   | 109,000 |   |   |   |   |   |   |   | 113,000 |   |
| Conversion      of Series B Preferred Stock       |   |                 | (22,165,000 | )      |              |   | (221,150 | )                 |   |   | 22,165,000  |   |   |                     | 221,650   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Sale      of Series C Preferred Stock             |   |                 | 15,766,155  |   |              |   | 157,662  |              |   |   |        |   |   |                     |      |   |   |   | 2,542,074 |   |   |   |   |   |   |   | 2,699,736 |   |
| Conversion      of Series C Preferred Stock       |   |                 | (14,766,155 | )      |              |   | (147,662 | )                 |   |   | 14,766,155  |   |   |                     | 147,662   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Deemed      Dividend – Preferred Stock      |   |                 |        |   |              |   |     |              |   |   |        |   |   |                     |      |   |   |   | 1,836,319 |   |   |   | (1,836,319 | ) |   |   |   |   |
| Accrued      Dividend paid in Common Stock        |   |                 |        |   |              |   |     |              |   |   | 225,770     |   |   |                     | 2,257     |   |   |   | 88,048 |   |   |   | (90,305 | ) |   |   |   |   |
| Net      (loss)                                   |   |                 |        |   |              |   |     |              |   |   |        |   |   |                     |      |   |   |   |   |   |   |   | (3,572,661 | ) |   |   | (3,572,661 | ) |
| Balance,      September 30, 2010                  |   |                 | 3,835,000   |   |              | $      | 38,350   |              |   |   | 107,699,540 |   |   | $                        | 1,076,995 |   |   | $ | 30,298,528 |   |   | $ | (24,243,755 | ) |   | $ | 7,170,118 |   |

----

|                                                                                            |   | Nine      Months EndedSeptember      30, |       |
|-------------------------------------------------------------------------------------------------|--------|------------------------------------------|------------|
|                                                                                            |   | 2010                                     |       |   | 2009 |   |
| OPERATING      ACTIVITIES:                                                                      |   |                                     |       |   |   |   |
| Net      (loss)                                                                                 |   | $                                        | (3,572,661 | ) |   | $ | (2,983,252 | ) |
| Adjustments      to reconcile net (loss) to net cash used in operating      activities:         |   |                                     |       |   |   |   |   |   |
| Depreciation      and amortization                                                              |   |                                     | 241,963    |   |   |   | 213,106 |   |
| Stock-based      compensation employees                                                         |   |                                     | 196,445    |   |   |   | 456,397 |   |
| Stock-based      compensation consultants                                                       |   |                                     | 15,282     |   |   |   | 147,690 |   |
|     Amortization      of prepaid financing costs                            |   |                                     | 114,658    |   |   |   | - |   |
|     Impairment      of LUMA equipment                                       |   |                                     | 1,025,373  |   |   |   | 155,755 |   |
|     Fair      market value of common stock issued for services              |   |                                     | 113,000    |   |   |   | - |   |
| Changes      in operating assets and liabilities:                                               |   |                                     |       |   |   |   |   |   |
| Accounts      receivable                                                                        |   |                                     | 30,771     |   |   |   | (1,075 | ) |
| Inventory                                                                                       |   |                                     | (102,080   | ) |   |   | 91,300 |   |
| Prepaid      expenses and other current assets                                                  |   |                                     | 16,141     |   |   |   | 104,497 |   |
| Accounts      payable                                                                           |   |                                     | (34,212    | ) |   |   | (74,399 | ) |
| Accrued      liabilities                                                                        |   |                                     | (89,494    | ) |   |   | 107,602 |   |
| Net      cash (used in) operating activities                                                    |   |                                     | (2,044,814 | ) |   |   | (1,782,379 | ) |
|                                                                                            |   |                                     |       |   |   |   |   |   |
| INVESTING      ACTIVITIES:                                                                      |   |                                     |       |   |   |   |   |   |
| Purchases      of fixed assets                                                                  |   |                                     | (3,315     | ) |   |   | (15,210 | ) |
| Net      cash (used in) investing activities                                                    |   |                                     | (3,215     | ) |   |   | (15,210 | ) |
|                                                                                            |   |                                     |       |   |   |   |   |   |
| FINANCING      ACTIVITIES:                                                                      |   |                                     |       |   |   |   |   |   |
|        Proceeds      from exercise of employee stock options |   |                                     | -          |   |   |   | 60,000 |   |
|        Proceeds      from issuance of Preferred Stock        |   |                                     | 2,699,736  |   |   |   | 1,434,640 |   |
|     Net      cash provided by financing activities                          |   |                                     | 2,699,736  |   |   |   | 1,494,640 |   |
|                                                                                            |   |                                     |       |   |   |   |   |   |
| Net      increase (decrease) in cash and cash equivalents                                       |   |                                     | 651,607    |   |   |   | (302,949 | ) |
|                                                                                            |   |                                     |       |   |   |   |   |   |
| CASH      AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                           |   |                                     | 3,408,237  |   |   |   | 1,618,181 |   |
|                                                                                            |   |                                     |       |   |   |   |   |   |
| CASH      AND CASH EQUIVALENTS AT END OF PERIOD                                                 |   | $                                        | 4,059,844  |   |   | $ | 1,315,232 |   |
|                                                                                            |   |                                     |       |   |   |   |   |   |
| Supplemental      disclosure of non-cash operating and financing activities:                    |   |                                     |       |   |   |   |   |   |
| Stock      issued at fair value for prepaid stock issuance cost                                 |   | $                                        | -          |   |   | $ | 273,504 |   |

----

The Company expects to incur significantadditional operating losses through at least the remaineder of 2010, as itcompletes clinical trials, begins outcome-based clinical studies and increasessales and marketing efforts to commercialize the WavSTAT System. If the Companydoes not receive sufficient funding, the Company may be unable to continue as agoing concern. The Company may incur unknown expenses or may not be able to meetits revenue forecast, and one or more of these circumstances would require theCompany to seek additional capital. The Company may not be able to obtain equitycapital or debt funding on terms that are acceptable. Even if the Companyreceives additional funding, such proceeds may not be sufficient to allow theCompany to sustain operations until it attains profitability and positive cashflows from operations. 

----

----

|                         |   | 2010         |   |   | 2009         |   |
|------------------------------|--------|--------------|--------|--------|--------------|--------|
| Expected      life           |   | 5      years |   |   | 5      years |   |
| Risk-free      interest rate |   |         | 2.02   | %      |         |   | 3.64 | % |
| Expected      volatility     |   |         | 118    | %      |         |   | 133 | % |
| Expected      dividend yield |   |         | 0      | %      |         |   | 0 | % |

----

|                                   |   |                           |      |   | Outstanding      Options     |
|----------------------------------------|--------|--------------------------------|-----------|--------|------------------------------|
|                                   |   | OptionsAvailable      ForGrant |      |   | Plan      OptionsOutstanding |   |   | WeightedAverageExercise      PricePer      Share |   | Weighted-AverageRemainingContractual      Term(years) |   | AggregateIntrinsicValue |
| December      31, 2009                 |   |                           | 3,071,392 |   |                         |   | 7,450,000 |   |   | $ | 0.54 |   | 7.71 |   |  - |
| Options      granted                   |   |                           | (800,000  | )      |                         |   | 800,000 |   |   | $ | 0.24 |   |   |   |   |
| Options      exercised                 |   |                           | -         |   |                         |   | - |   |   |   | - |   |   |   |   |
| Options      forfeited                 |   |                           | 50,000    |   |                         |   | (50,000 | ) |   | $ | 0.80 |   |   |   |   |
| Additional      options authorized     |   |                           | 5,633,537 |   |                         |   |   |   |   |   |   |   |   |   |   |
| Outstanding      at September 30, 2010 |   |                           | 7,954,929 |   |                         |   | 8,200,000 |   |   | $ | 0.51 |   | 7.22 |   | - |
| Exercisable      at September 30, 2010 |   |                           |      |   |                         |   | 5,150,000 |   |   | $ | 0.63 |   | 6.28 |   | - |

|                |   | September      30,2010 |    |   | December      31,2009 |   |
|---------------------|--------|------------------------|---------|--------|-----------------------|--------|
| Raw      materials  |   | $                      | 208,826 |   |                  | $      | 175,527 |   |
| Finished      goods |   |                   | 298,929 |   |                  |   | 230,148 |   |
| Totals              |   | $                      | 507,755 |   |                  | $      | 405,675 |   |

----

----

|   | · | Continue      selling the WavSTAT System in the international and U.S. for the      detection and treatment of pre-cancer and cancer of the    colon. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Complete      WavSTAT System clinical trials related to the diagnosis of esophageal      cancers. |
|--------|--------|---------------------------------------------------------------------------------------------------|

|   | · | To      continue the design and planning for the next generation of our      fluorescence-based systems. |
|--------|--------|----------------------------------------------------------------------------------------------------------|

----

----

Item3.Quantitative andQualitative Disclosures About Market Risk

| PART      II | OTHER      INFORMATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Item 1.      | Legal      Proceedings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|         | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Item 1A.     | Risk      Factors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|         | There      have been no material changes in our risk factors from those disclosed in      Part I, Item 1A, of our Annual Report on Form 10-K for the fiscal year      ended December 31, 2009.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Item 2.      | Unregistered      Sales of Equity Securities and Use of Proceeds                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|         | On      August 31, 2010, the Company issued 15,000 shares of common stock to a      vendor for services. The fair value of the shares was determined to be      $2,400, and the Company recognized expense in the amount of $2,400, based      upon the market value of the common stock on the date of issuance. This      transaction was deemed to be exempt from the registration requirements of      the Securities Act of 1933 pursuant to Section 4(2) of the Securities Act      of 1933.   On      July 26, 2010, the Company issued 210,000 shares of common stock to a      vendor for services. The fair value of the shares was determined to be      $52,500, and the Company recognized expense in the amount of $52,500,      based upon the market value of the common stock on the date of      issuance.  This transaction was deemed to be exempt from the      registration requirements of the Securities Act of 1933 pursuant to      Section 4(2) of the Securities Act of    1933.    |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Item 3.      | Defaults      Upon Senior Securities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|         | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Item 4.      | (Removed      and Reserved)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Item 5.      | Other      Information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Item 6.      | Exhibits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 31.1         | Certification      of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley      Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 31.2         | Certification      of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley      Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 32.1         | Certification      of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley      Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 32.2         | Certification      of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley      Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

----

  

|                         | SpectraScience,      Inc.(Registrant) |                                                                |
|------------------------------|---------------------------------------|---------------------------------------------------------------------|
|                         |                                  |                                                                |   |
| Date:      November 15, 2010 |                                  | /s/      Mark McWilliams                                            |   |
|                         |                                  | Mark      McWilliams                                                |
|                         |                                  | Chairman      of the Board and Interim Chief Executive Officer      |
|                         |                                  | (Principal      executive officer)                                  |
|                         |                                  |                                                                |
|                         |                                  |                                                                |   |
| Date:      November 15, 2010 |                                  | /s/      James Dorst                                                |   |
|                         |                                  | James      Dorst                                                    |
|                         |                                  | Chief      Financial Officer and Chief Operating Officer            |
|                         |                                  | (Principal      financial officer and principal accounting officer) |
|                         |                                  |                                                                |   |

----